207_Combined course Presentations

Toxicity of concurrent SRT and tyrosine kinase inhibitors (TKIs)

EGF-R-inhibitors (gefitinib, erlotinib, lapatinib)

 Concurrent EGF-R-targeting TKIs and extra-cranial SRT: increased toxicity within the irradiated volume in the treatment of abdominal and thoracic metastases

 No increased toxicity in cranial SRT

 Data on lapatinib+SRT is not available.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37